Latest Breaking News On - Bold therapeutics - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024

/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that.

San diegoUnited statesSouth koreaBritish columbiaSoult ukpyolsiE russell mcallisterJim pankovichClinical development at bold therapeuticsBold therapeutics incPreclinical development at bold therapeuticsSeoul national university college of medicineBold therapeuticsSeoul national university collegePancreatic ductal adenocarcinomaCellular stress responsesPancreatic ductal

Contineum lowers expectations for $110M IPO

Contineum lowers expectations for $110M IPO
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Contineum therapeuticsSan diego basedNasdaq global select marketBold therapeuticsPipeline therapeutics

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesLauren walkerEdwin tuckerAlex grayJoyce allaireJasper therapeutics incAmerican academy of allergyAnnual meetingKit mouseWendy pangSenior vice presidentChief medicalAbstract titlePrevents passive systemic anaphylaxisMice expressing chimeric humanMast cell depletion poster number

Jasper Therapeutics (JSPR) Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology

Jasper Therapeutics (JSPR) Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEdwin tuckerJasper therapeutics incAmerican academy of allergyJasper therapeuticsAnnual meetingKit mouseWendy pangSenior vice presidentChief medicalAbstract titlePrevents passive systemic anaphylaxisMice expressing chimeric humanMast cell depletion poster numberTherapeutic trialsAllergic skin disorders